The REVELUTION (Relugolix versus Leuprolide Cardiac) trial compared coronary plaque after 2 types of androgen deprivation therapy (ADT) for prostate cancer.

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer? This is an ASCO Meeting Abstract from the ...

Differences in Patient-Reported Outcome Measures in Patients With Cancer Six Months Before Death All premenopausal patients who underwent first HSCT from June 2016 to January 2022 were included in ...

Based on EMBARK data, both enzalutamide monotherapy and combination therapy (with leuprolide) reduced the likelihood of distant metastasis in patients with high-risk biochemically recurrent prostate ...

The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically ...

Leuprolide acetate 45mg; per kit; depot susp for IM inj; preservative-free. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). <1yr: not established. ≥1yrs: ...